SCHEMBL13699151

SCHEMBL13699151

CCC(CC)NC(=O)Nc1ccc(Oc2ccc(NC(=O)c3ccc(OC4CC5CCC(C4)N5C)c(Cl)c3)cc2)c(OC)c1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 4/20 0.43
RAB9A P51151 4/20 0.43
MAPT P10636 4/20 0.43
SMN1; SMN2 Q16637 3/20 0.43
PKM P14618 1/20 0.43
KMT2A Q03164 6/20 0.41
MEN1 O00255 5/20 0.41
MCHR1 Q99705 2/20 0.41
CYP2D6 P10635 1/20 0.41
CASP3 P42574 1/20 0.41
SENP7 Q9BQF6 1/20 0.41
ALDH1A1 P00352 2/20 0.40
TP53 P04637 1/20 0.40
TAS1R3 Q7RTX0 1/20 0.40
TAS1R1 Q7RTX1 1/20 0.40
KDM4E B2RXH2 2/20 0.39
PDE4A P27815 1/20 0.39
PDE4B Q07343 1/20 0.39
PDE4C Q08493 1/20 0.39
PDE4D Q08499 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13699133 0.94 PKM (0.45) NPC1RAB9AMAPTSMN1; SMN2PKM
SCHEMBL13699277 0.92 PKM (0.45) NPC1RAB9AMAPTSMN1; SMN2PKM
SCHEMBL13699206 0.91 PKM (0.45) NPC1RAB9AMAPTSMN1; SMN2PKM
SCHEMBL13699146 0.89 PNLIP (0.45) NPC1RAB9AMAPTSMN1; SMN2PKM
SCHEMBL13699296 0.89 PKM (0.42) SMN1; SMN2PKMKMT2AMEN1MCHR1
SCHEMBL4237451 0.88 SMN1; SMN2 (0.44) NPC1RAB9AMAPTSMN1; SMN2PKM
SCHEMBL4229209 0.86 PKM (0.43) NPC1RAB9AMAPTSMN1; SMN2PKM
SCHEMBL13699252 0.86 PKM (0.44) NPC1RAB9AMAPTSMN1; SMN2PKM
SCHEMBL13699258 0.86 PKM (0.44) NPC1RAB9AMAPTSMN1; SMN2PKM
SCHEMBL13699253 0.86 MCHR1 (0.43) NPC1RAB9AMAPTSMN1; SMN2PKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090233910-A1 Npy antagonists, preparation and uses CEREP (FR) 2009-09-17 US disclosed
US-20090233910-A1 Npy antagonists, preparation and uses CEREP (FR) 2009-09-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090233910-A1 Npy antagonists, preparation and uses NPY1R, NPY5R, NPY2R NPC1 2338/4885RAB9A 2492/4885MAPT 1398/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.